For decades, Alzheimer’s disease has been one of medicine’s most stubborn mysteries. Scientists have identified amyloid plaques, tau tangles, inflammation, metabolic dysfunction and changes in the way aging brain cells communicate — yet stopping the disease remains extraordinarily difficult.

Now an unexpected area of research is attracting attention: peptides.

Some peptide and peptide-based therapies are being investigated for their ability to influence memory, brain signaling, toxic amyloid proteins and abnormal tau. Most importantly, several have already moved beyond animal experiments and into human clinical trials.

One improved measures of cognition in older adults with mild cognitive impairment. Another was specifically engineered to dismantle toxic amyloid-beta oligomers. A peptide vaccine is teaching the immune system to recognize abnormal tau. And insulin — itself a peptide hormone — has been delivered through the nose in an attempt to influence the brain directly.

None has been proven to cure or reverse Alzheimer’s disease. But together, these studies offer an intriguing glimpse at where Alzheimer’s research may be heading.

Here are 4 peptide therapies scientists are watching.

1 Tesamorelin — The Peptide That Improved Cognition in Humans

Tesamorelin may be the biggest surprise on this list.

It is a synthetic, stabilized analogue of growth hormone-releasing hormone, or GHRH. Rather than simply supplying growth hormone, tesamorelin stimulates the pituitary gland and increases signaling through the growth hormone–IGF-1 pathway.

Why would that matter to your brain?

Because GHRH, growth hormone and IGF-1 — insulin-like growth factor 1 — naturally decline with age, and these signaling systems have important roles in brain function.

Researchers at the University of Washington put the idea to the test in a randomized, double-blind, placebo-controlled trial involving 152 adults ages 55 to 87.

Even more interesting, 66 participants had mild cognitive impairment, or MCI — a condition that can precede Alzheimer’s dementia in some people.

Participants received either placebo or 1 milligram of tesamorelin daily for 20 weeks.

The results were impressive enough to get attention.

Researchers reported a statistically significant beneficial effect on overall cognition, with favorable effects seen in healthy older adults as well as participants with MCI. Executive function also improved, and the MCI group showed favorable effects on verbal memory.

This wasn’t simply a group of people saying they felt mentally sharper. Researchers used standardized neuropsychological testing to measure performance.

Tesamorelin also increased circulating IGF-1 by approximately 117%, while average levels remained within the normal physiological range.

Researchers then looked even deeper.

A smaller randomized substudy involving 30 adults, including 17 with MCI, used magnetic resonance spectroscopy to examine brain chemistry. After 20 weeks, researchers found treatment-related changes involving GABA, one of the brain’s major neurotransmitters.

That means scientists observed more than a change in a blood test. They found measurable cognitive effects alongside changes in brain neurochemistry.

There is an important distinction, however: MCI is not the same thing as Alzheimer’s disease, and not everyone with MCI progresses to dementia. This study did not prove that tesamorelin prevents or reverses Alzheimer’s.

What it did demonstrate is compelling enough: manipulating an age-related hormonal signaling pathway produced measurable cognitive benefits in older human beings.

That deserves a bigger study.

2 PRI-002 — The Peptide Designed to Break Apart Toxic Amyloid

Imagine designing a tiny molecule with one unusual assignment:

Find toxic clusters of amyloid-beta and break them apart.

That is essentially the idea behind PRI-002.

Most people have heard of the amyloid plaques found in the brains of people with Alzheimer’s. But researchers are also intensely interested in smaller clusters called amyloid-beta oligomers.

These soluble oligomers are considered particularly harmful because they can interfere with communication between neurons and damage synaptic function.

PRI-002 is an experimental all-D-enantiomeric peptide engineered to disassemble toxic amyloid-beta oligomers into non-toxic monomers.

And scientists have now tested it in humans.

A randomized, double-blind Phase 1b clinical trial published in Nature Communications in 2025 recruited adults ages 50 to 80 with mild cognitive impairment or mild dementia due to Alzheimer’s disease.

Twenty people were recruited, and 19 were randomized and completed the trial.

Participants received either 300 milligrams of oral PRI-002 once daily or placebo for 28 days.

The study was primarily designed to evaluate safety, tolerability and pharmacokinetics.

PRI-002 was reported to be well tolerated, with no serious adverse events.

Then researchers noticed something interesting.

At the Day 56 follow-up, participants who had received PRI-002 performed significantly better than the placebo group on the CERAD word-list memory test.

Before anyone starts calling this an Alzheimer’s breakthrough, there is an enormous caveat.

This was a tiny study.

With fewer than 20 participants completing the trial and only 28 days of treatment, it cannot establish whether PRI-002 slows Alzheimer’s disease. The researchers themselves described the cognitive results as hypothesis-generating.

But consider how far the idea has traveled.

Scientists identified toxic amyloid oligomers.

They engineered a peptide intended to dismantle them.

They moved that peptide into people with MCI or mild Alzheimer’s dementia.

And an intriguing memory signal appeared.

Sometimes that is exactly how a much bigger scientific story begins.

3 AADvac1 — The Peptide Vaccine Going After Tau

Amyloid gets most of the publicity, but Alzheimer’s has another infamous protein:

Tau.

Healthy tau helps stabilize microtubules — microscopic structures that act somewhat like an internal transportation network inside neurons.

In Alzheimer’s disease, tau becomes abnormal and can accumulate into the neurofibrillary tangles characteristic of the disease.

As tau pathology spreads through vulnerable regions of the brain, it is closely associated with neurodegeneration and worsening cognitive impairment.

Scientists therefore tried something fascinating.

Instead of continually giving patients antibodies against tau, what if they could teach the immune system to recognize pathological tau itself?

Enter AADvac1.

AADvac1 is a peptide-based vaccine designed to generate antibodies against abnormal forms of tau.

The Phase 2 ADAMANT trial enrolled 196 people with mild Alzheimer’s disease and followed them for approximately two years.

Participants receiving AADvac1 developed strong antibody responses against the vaccine’s tau target, and the treatment was generally well tolerated.

The vaccine also produced effects on biomarkers associated with neurodegeneration.

But this is where Alzheimer’s research reminds us how complicated the brain really is.

Across the entire study population, AADvac1 did not produce a statistically significant improvement in the main cognitive and functional outcomes.

Researchers kept digging.

A later post-hoc analysis examined 137 participants who were positive for plasma p-tau217, an increasingly important Alzheimer’s-associated biomarker.

Among this subgroup, AADvac1 was associated with a 56% lower rate of increase in neurofilament light and a 73% lower rate of increase in GFAP — biomarkers associated with neurodegeneration and neuroinflammation.

Those numbers sound dramatic, but the clinical differences still did not reach statistical significance. Because this was a post-hoc subgroup analysis, the findings need confirmation in larger prospective trials.

Still, the concept itself is remarkable.

Scientists successfully used a peptide vaccine to make the human immune system recognize pathological tau.

Whether that ultimately translates into meaningful preservation of memory remains one of the big questions.

4 Intranasal Insulin — The Peptide Hiding in Plain Sight

One of the most familiar medicines in the world is also a peptide.

Insulin.

We normally associate insulin with blood sugar, diabetes and the pancreas.

But insulin also has important functions inside the brain.

Insulin receptors are found throughout brain regions involved in memory and cognition, and insulin signaling influences glucose metabolism, synaptic function and neuronal communication.

That led researchers to an unusual question:

Could insulin be delivered through the nose to influence the brain?

The nasal route attracted attention because it may allow insulin to reach the central nervous system while limiting its effects on blood glucose elsewhere in the body.

An early randomized pilot trial included 104 adults with amnestic MCI or mild-to-moderate Alzheimer’s disease.

Participants received placebo or intranasal insulin for four months.

Researchers reported preservation or improvement in certain measures of memory and functional ability, along with changes in some Alzheimer’s-related biomarkers.

Another randomized study involving 60 adults with MCI or Alzheimer’s disease found that 40 IU of intranasal insulin detemir improved a memory composite compared with placebo, although responses differed according to APOE genotype.

Then came a larger test.

A randomized clinical trial involving 289 adults with MCI or Alzheimer’s dementia studied intranasal insulin during a 12-month blinded treatment period.

In the trial’s primary analysis, researchers found no significant cognitive or functional benefit compared with placebo. Problems with the insulin-delivery devices complicated interpretation of the results.

That may sound disappointing, but it is actually a beautiful example of why science requires repetition.

Small trials uncover possibilities.

Large trials test whether those possibilities hold up.

And negative findings can be every bit as valuable as positive ones.

4 Peptides, 4 Completely Different Strategies

Perhaps the most interesting part of this story isn’t any single peptide.

It’s how differently they approach the aging brain.

Tesamorelin stimulates the GHRH-growth hormone-IGF-1 pathway and has demonstrated measurable cognitive benefits in older adults, including people with MCI.

PRI-002 is designed to physically dismantle toxic amyloid-beta oligomers and has now reached human testing in people with MCI or mild Alzheimer’s dementia.

AADvac1 uses a peptide vaccine to teach the immune system to recognize pathological tau.

Intranasal insulin targets insulin signaling and brain metabolism.

One pathway involves growth factors.

One targets amyloid.

One targets tau.

One targets metabolism.

That diversity may be telling us something important.

Alzheimer’s probably isn’t one broken switch waiting for one magic drug.

The disease involves an enormously complicated network of amyloid accumulation, tau pathology, inflammation, vascular health, metabolic changes, mitochondrial function, synaptic dysfunction and eventually neuronal death.

The future of Alzheimer’s treatment may therefore involve addressing several biological pathways — potentially at different stages of the disease.

Where Does the Science Stand Today?

These studies do not establish peptides as a cure for Alzheimer’s disease.

Tesamorelin has not been proven to prevent Alzheimer’s, despite encouraging cognitive results in people with MCI.

PRI-002 remains in very early clinical development.

AADvac1 generated an immune response against pathological tau but did not significantly improve the primary clinical outcomes across its overall Phase 2 population.

Intranasal insulin has produced encouraging findings in some studies and disappointing findings in others.

But there is another way to look at the story.

Scientists are no longer simply observing Alzheimer’s pathology after the damage has occurred.

They are designing molecules to interfere with specific biological processes involved in brain aging and neurodegeneration — and testing those ideas in actual people.

That is progress.

Not a cure.

Not a promise.

But progress.

And sometimes medicine moves forward exactly like this:

A molecule.

A hypothesis.

A handful of patients.

A surprising memory score.

A larger clinical trial.

And eventually — if the science holds up — a completely new way of treating disease.

For the millions of families touched by Alzheimer’s, these peptides aren’t answers yet.

But they are questions worth asking.

At MindBodySpiritLife.com, we believe understanding emerging science helps us ask better questions about our bodies, our brains and the future of medicine. Visit often as we explore peptides, longevity, nutrition, brain health and the discoveries changing what we know about human health. And if you have knowledge, experiences or a story that could inspire someone else, come share it with us.

Let’s Inspire One Another.